[
    [
        {
            "time": "",
            "original_text": "中药饮片和保健食品混为一谈？“灵芝第一股”寿仙谷被指涉嫌虚假宣传 欺诈造假",
            "features": {
                "keywords": [
                    "中药饮片",
                    "保健食品",
                    "虚假宣传",
                    "欺诈造假",
                    "寿仙谷"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "中药饮片和保健食品混为一谈？“灵芝第一股”寿仙谷被指涉嫌虚假宣传 欺诈造假",
                "Correlation": 9,
                "Sentiment": 2,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "步长制药回复年报问询函 医药行业销售费用和研发投入受关注 问询",
            "features": {
                "keywords": [
                    "步长制药",
                    "年报问询",
                    "销售费用",
                    "研发投入"
                ],
                "sentiment_score": -0.3,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "步长制药回复年报问询函 医药行业销售费用和研发投入受关注 问询",
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 6,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 7,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "又一中药注射剂企业收问询函！年入2.64亿的瓜蒌皮注射液被关注 问询",
            "features": {
                "keywords": [
                    "中药注射剂",
                    "问询函",
                    "瓜蒌皮注射液"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "又一中药注射剂企业收问询函！年入2.64亿的瓜蒌皮注射液被关注 问询",
                "Correlation": 8,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 7,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "易明医药去年利润腰斩 两票制后主营药品毛利从76%降至4%",
            "features": {
                "keywords": [
                    "易明医药",
                    "利润腰斩",
                    "两票制",
                    "毛利率下降"
                ],
                "sentiment_score": -0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "易明医药去年利润腰斩 两票制后主营药品毛利从76%降至4%",
                "Correlation": 10,
                "Sentiment": 2,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "步长制药如何花掉80亿销售费？深夜回复可不简单！",
            "features": {
                "keywords": [
                    "步长制药",
                    "销售费用",
                    "80亿"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "步长制药如何花掉80亿销售费？深夜回复可不简单！",
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业2019q1业绩前瞻-2019q1医药板块整体增长稳健，个股业绩持续分化",
            "features": {
                "keywords": [
                    "医药生物",
                    "2019q1",
                    "业绩增长",
                    "个股分化"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业2019q1业绩前瞻-2019q1医药板块整体增长稳健，个股业绩持续分化",
                "Correlation": 6,
                "Sentiment": 6,
                "Importance": 7,
                "Impact": 5,
                "Duration": 7,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 6,
                "Headline_Structure": 6,
                "Source_Recency": 5
            }
        }
    ]
]